Investing
Payments To Acquire Intangible Assets1
Regeneron Pharmaceuticals Payments To Acquire Intangible Assets1 increased by 16.4% to $48.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.9%, from $42.20M to $48.90M. Over 3 years (FY 2022 to FY 2025), Payments To Acquire Intangible Assets1 shows a downward trend with a -32.5% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher spending indicates a strategic focus on external R&D and pipeline expansion.
Detailed definition
This captures cash outflows for the acquisition of non-physical assets such as patents, licenses, intellectual property,...
Peer comparison
High for pharmaceutical and technology firms that rely on acquiring external innovation to supplement internal R&D.
Metric ID:
investing_payments_to_acquire_intangible_assets1Historical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $926.80M | $100.00M | $100.90M | $20.90M | $23.90M | $62.10M | $27.90M | $30.40M | $0.00 | $67.40M | $42.20M | $187.80M | $43.30M | $42.00M | $48.90M |
| QoQ Change | — | — | — | — | -89.2% | +0.9% | -79.3% | +14.4% | +159.8% | -55.1% | +9.0% | -100.0% | — | -37.4% | +345.0% | -76.9% | -3.0% | +16.4% |
| YoY Change | — | — | — | — | — | — | — | -97.4% | -37.9% | -72.3% | +45.5% | -100.0% | +8.5% | +51.3% | +517.8% | — | -37.7% | +15.9% |
Range$0.00 – $926.80M
Avg YoY Growth+29.4%
Median YoY Growth-14.6%
Payments To Acquire Intangible Assets1 at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's payments to acquire intangible assets1?
- Regeneron Pharmaceuticals (REGN) reported payments to acquire intangible assets1 of $48.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's payments to acquire intangible assets1 changed year-over-year?
- Regeneron Pharmaceuticals's payments to acquire intangible assets1 increased by 15.9% year-over-year, from $42.20M to $48.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's payments to acquire intangible assets1?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's payments to acquire intangible assets1 has grown at a -32.5% compound annual growth rate (CAGR), from $1.03B to $315.30M.
- What does payments to acquire intangible assets1 mean?
- Cash spent to acquire intellectual property, patents, or other non-physical assets.